BioNTech Boosts German Investment With Expansion of Vaccine Hub

BioNTech SE has completed construction at a German facility for making a key ingredient in its messenger-RNA vaccines, the sort of investment that pharma leaders fear is becoming less attractive in Europe.
Read More

About The Author

Jonathan Jeriah

See author's posts